Latest Content

Treatment Switching May Be Less Likely With Brukinsa vs Other BTK Inhibitors in CLL/SLL

September 17th 2024, 1:00pm

By Jax DiEugenio

Article

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic lymphocytic leukemia.

Presurgical Cetrelimab With TAR-200 Shows Responses in Muscle-Invasive Bladder Cancer

September 16th 2024, 10:00pm

By Kristi Rosa

Article

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows.

AI May Predict Cancer Mutations in Lung, Other Cancers

September 16th 2024, 9:00pm

By Darlene Dobkowski, MA

Article

An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.

Breastfeeding Is OK in Breast Cancer Subset During Hormone Therapy Break

September 16th 2024, 7:00pm

By Ariana Pelosci

Article

In patients with HR-positive breast cancer who recently gave birth, breastfeeding is OK during a break from receiving hormone therapy.

Several Resources I Counted on During Treatment for AML

September 16th 2024, 5:00pm

By Mary Sansone

Article

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were available to me.

Targeted Therapy Outperforms Standard Care in Metastatic Solid Cancers

September 16th 2024, 4:29pm

By Brielle Benyon

Article

Patients with metastatic disease whose cancers were tested and treated for specific mutations tended to have better outcomes than those given the standard of care.

Therapies for Some With Prostate Cancer Focuses on Reducing Side Effects

September 16th 2024, 3:00pm

By Darlene Dobkowski, MA

Video

At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.

Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC

September 16th 2024, 1:00pm

By Russ Conroy

Article

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with Imfinzi versus placebo.

Perioperative Imfinzi, Neoadjuvant Chemo Improves Survival in Muscle-Invasive Bladder Cancer

September 15th 2024, 10:19pm

By Courtney Flaherty

Article

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer.

Enhertu Maintains Quality of Life in Metastatic Breast Cancer Subgroup

September 15th 2024, 8:39pm

By Jonah Feldman

Article

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and -ultralow metastatic breast cancer.

Cyramza Plus Lonsurf Did Not Improve Survival in Metastatic Colorectal Cancer

September 15th 2024, 8:00pm

By Caroline Seymour

Article

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated metastatic colorectal cancer.

Chemotherapy De-Escalation Associated With Excellent HR+/HER2+ Breast Cancer Survival

September 15th 2024, 7:30pm

By Alex Biese

Article

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta followed by response-guided chemotherapy experienced “exceptionally excellent” survival outcomes.

Outcomes, Lymphedema Risk May Be Similar With Hypofractionated Versus Normofractionated Radiation in Early Breast Cancer

September 15th 2024, 7:00pm

By Darlene Dobkowski, MA

Article

Hypofractionated radiation was noninferior to normofractionated radiation in patients with early breast cancer regarding lymphedema risk.

Presurgical Keytruda-Chemo Combo With Postsurgical Keytruda May Improve Survival in Early TNBC

September 15th 2024, 6:25pm

By Chris Ryan

Article

Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus chemotherapy and postsurgical Keytruda.

Antibody-Drug Conjugate Is Tolerable, Active in CLDN6-Positive Solid Tumors Including Ovarian Cancer

September 15th 2024, 5:52pm

By Chris Ryan

Article

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.